Techedge Inc. (OTCBB: TEDG) (fka TEDG)

[sweet crude]

TEDG - ships flu vaccine to Macedonia

China Biopharma Receives Order to Export Flu Vaccine to Macedonia
Thursday September 7, 9:00 am ET


HANGZHOU, China--(BUSINESS WIRE)--Sept. 7, 2006--China Biopharma Inc. (OTCBB: TEDG - News) today announced that Zhejiang Tianyuan Biotech, the Company's China subsidiary, has received an export letter of credit from the Government of Macedonia to ship its flu vaccine product to this Southeastern European country for distribution.

http://finance.yahoo.com/q?s=TEDG.OB

[sweet crude]

China bioPharma - flu vaccine news

China Biopharma Inc. Manufacturing Partner Receives SFDA Approval to Deliver Flu Vaccine for the First Batch Release of the 2006-2007 Season
Thursday August 31, 9:00 am ET


HANGZHOU, China--(BUSINESS WIRE)--Aug. 31, 2006--China Biopharma Inc. (OTCBB: TEDG - News) today announced that Zhejiang Tianyuan Biopharmaceutical, the Company's manufacturing joint venture partner, received approval from the Chinese State Food and Drug Administration (SFDA) to deliver its flu vaccine product for the first batch release of the 2006-2007 influenza season. The Company commenced shipping of the first lots of its flu vaccine product last week to local Centers for Disease Control & Prevention (China CDCs) and hospitals.

http://finance.yahoo.com/q?s=TEDG.OB

[silverfox1155]

Techedge Inc. Projects $10,000,000 in Sales for 2006
Tuesday July 18, 9:00 am ET


http://biz.yahoo.com/bw/060718/20060718005563.html?.v=1

[sweet crude]

news out

China BioPharma Issues Profile on TheAsianInvestor.com

ISELIN, N.J., May 25, 2006 (BUSINESS WIRE) -- Techedge Inc. (OTCBB:TEDG) announced that China BioPharma, Ltd. has issued a company profile on Chinese investment website The Asian Investor.

Investors can view the company report by going to www.theasianinvestor.com

Peter Wang commented, "The Company is pleased to make this first step in launching our investor awareness campaign for China BioPharma, Ltd., as one of China's largest non-government owned human vaccine production companies. The Company is involved in the research and production of human vaccines for highly contagious diseases such as Bird Flu, EHF, and a number of Influenza viruses."

About China BioPharma

China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (EHF) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize.

[sweet crude]

TEDG moving up on Bird Flu news

news out of Indonesia sending bird flu plays flying!

[sweet crude]

China BioPharma (TEDG) - bird flu vaccine

Im surprised TEDG isnt generating more interest with what they have.

- almost $10 million in vaccine sales last year
- around $1.5 million in net income (profitable)
- CEO headed China division for Chiron Vaccines
- Board of Advisors has a number of BIG names on board
- They have a Influenza vacine in market
- Doing research on H5N1 virus
- Doing research on SARS virus
- over 140 employees & researchers
- one of China's largest non-governmental vaccine producers

[sweet crude]

TEDG - Board of Advisors (WOW!!)

This is powerful!

* Mr. Jean-Louis Chanas - former President of Aventis Pasteur International
* Mr. John Lambert - former President of Chiron Vaccines
* Pr Dakui Yin - former Vice-Ministry of Health, former Chairman of the China Association of Preventable Medicine
* Pr Liming Li - Dean of College of Public Health of Peking University, former Director General of the China National Center for Disease Control
* Mr. Kai Zhao - Academician of the China Academy of Engineering, former Director of Beijing Institute of Biological Products
* Mr. Yongxin Yu - Academician of the China Academy of Engineering
* Pr and Ms. Xiexiu Wang - Member of the WHO (World Health Organization) Technical Advisory Group on Tuberculosis, Vice Chairman of the China Association of Preventive Medicine, Director of Tianjin Municipal Center for Disease Control and Prevention.

http://www.theasianinvestor.com/reports/tedg.htm

[sweet crude]

STTK, HEB, GNBT, SVA, TEDG

RANK BY SECTOR MARKET CAP

Ranked by market caps dated April 12, 2006. NOTE: TEDG currently has one of lowest market caps at $41 million for this sector group.

GNBT = $235 million
HEB = $180 million
SVA = $158 million
STTK = $68.9 million
TEDG = $41 million


RANK BY FISCAL 2005 REVENUES

Revenues for the trailing 12 months. NOTE: TEDG did the most revenue at $10 million for this sector group. Investors are advised to check current SEC filings as some of these numbers may have changed over the running quarter.

TEDG = $10 million
SVA = $6.8 million
HEB = $1 million
STTK = $756k
GNBT = $260k


RANK BY SHARE PRICE

NOTE: TEDG is trading for the lowest price in this sector group as of closing bell on April 12, 2006.

HEB = $2.95
GNBT = $2.65
SVA = $1.95
STTK = $0.64
TEDG = $0.50


SHARE PRICE IF TEDG TRADED AT COMPETITOR MARKET CAPS

GNBT ($235 mrkt cap) = $2.86 a share
HEB ($180 mrkt cap) = $2.19 a share
SVA ($158 mrkt cap) = $1.95 a share
STTK ($68.9 mrkt cap) = $0.84 a share

TEDG (current price) = $0.50


The best comparison should be with SVA, as it's also a vaccine research company based out of China like TEDG, and did around $6.8 million in revenues for fiscal 2005. We should give SVA a premium above TEDG for being on the AMEX exchange, lets say 50% to be conservative. SVA is currently trading at $1.95 share price. If TEDG were trading at say $1.30 a share, then 50% above that price is SVA at $1.95. (50% of $1.30 = .65 + $1.30 = $1.95 or SVA current share price). Note: TEDG did almost 50% more in sales revenue as compared to SVA for fiscal 2005. TEDG should be trading, fairly, around $1.30 per share compared to others in the bird flu sector.

http://www.theasianinvestor.com/reports/tedg.htm

[sweet crude]

H5N1 research

With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees.

http://biz.yahoo.com/bw/060410/20060410005384.html?.v=1

[ballyhooo]

Techedge Inc. Signs Definitive Agreement to Acquire China BioPharma Ltd.
Business Wire - April 10, 2006 08:15

ISELIN, N.J., Apr 10, 2006 (BUSINESS WIRE) -- Techedge Inc. (OTCBB:TEDG) is pleased to announce the acquisition of China BioPharma Limited (CBP), a Cayman Island company, which has majority ownership rights to Tianyuan Bio-pharmaceuticals Co. Ltd., based out of Zhejiang Province, China. Currently, this deal arrangement is pending on the Chinese government's final approval.

Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (Ebola) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize.

Tianyuan Bio-pharmaceutical Co., Ltd. plans to establish the production of 3 to 5 new products to its research portfolio of vaccines, with 3 major in the series of aspects of bacterial, virus, and viral vaccines, having already accomplished a batch of technical achievements with autonomous intellectual property. With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as SARS, and avian H5N1 influenza (bird flu). The company currently has around 140 employees. For more information on their current vaccines please visit www.ty-pharm.com

MANAGEMENT

The recent appointment of Dr. Shu as China BioPharma's new Chief Research Scientist and CEO brings to the company additional creativity and years of management expertise in the field of vaccine research. Formerly the Far East & North Pacific Regional Executive Director of Chiron Vaccines, Dr. Shu is widely recognized in the vaccine field in China.

Dr. Shu brings extensive experiences in the areas of business start-ups, general management within the vaccine industry, and a proven track record in medical and marketing management in both France and China. His past professional experiences include General Delegate of China for Aventis Pasteur, and the Medical and Regulatory Affairs Manager for Pasteur Merieux Connaught, based in Lyon, France. Dr Shu was also the author of several articles and books in vaccine research.

Aside to Dr. Shu, the company has brought together an International Advisory Board of some of the top experts in the field of vaccine research within global health organizations.

FINANCIALS

For fiscal year 2005, Tianyuan Bio-pharmaceutical Co., Ltd. realized $9 million in sales, with a net profit of $1.5 million for the year, unaudited. The company is in the final process of completing independent audits to US GAAP standards, which should be available for public review shortly.

According to the agreement, Techedge Inc. will acquire 100% of the outstanding capital stock of CBP in exchange for 3,000,000 unregistered shares of Techedge's common stock to be issued.

"With this acquisition, together with China BioPharma, we will bring more international expertise, technologies, and management into Tianyuan Bio-Pharmaceutical and help expand the marketing capability beyond China. This acquisition will make Tianyuan Bio-Pharmaceutical a much stronger company," Peter Wang, CEO of Techedge stated.

About Techedge Inc.

Techedge Inc. (OTCBB:TEDG) is a leading developer of mobile VoIP and wireless broadband solution provider. The Company has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. For more information, please visit its website at www.techedgeinc.net

[silverfox1155]

I'm in and out and gonna get back in STTK. Looking closely here as the two companies are not conflicting. Seems TEDG has good chance of vaccine for bird flu for far east. Gonna study charts today and find several entry points. Looks as tho nice movement yesterday with MACD breaking to the upside. Time to make a decision here IMO.

[sweet crude]

TEDG DD info

- Acquiring one of China's biggest flu vaccine producer
- Did $10 mill in sales last year
- Did $1.5 mill in profit
- Has a flu vaccine already in the market
- Doing research on H5N1
- New CEO has 'real' background in flu vaccines
- TEDG not hyped and still cheap
- 82 mill outstanding
- Short term price target = $1.20


VALUATION RATING

Reflecting the size of TianYuan Bio-pharmaceutical research facilities and extensive background in vaccine research, and their stated revenues of $10 million for fiscal 2005, we feel it to be 'fair' to give TEDG a target market cap value of $100 million as compared to other bird flu vaccine producers trading today. TEDG currently has 82 million shares issued and outstanding, which would give TEDG a short-term valuation price target of around $1.20 a share.

http://www.theasianinvestor.com/reports/tedg.htm

[piranha_trader]

Well I hope you guys know that STTK is involved with survelliance and will be trying to head off the contamination of fowl resources allover the world.

Totally different market.


Plus from what I can tell STTK does have something here. Enough to where its overview is being requested by several nations including China, Indonesia, and the United States.

[sweet crude]

unbelievable

Im so surprised we dont have more action on this thing, especially compared to STTK which has nothing really.

- Largest non-governmental vaccine firm in China
- Have 2 vaccines out now for Ebola and Influenza
- Appoint Dr. Shu CEO, who used to run Chiron's viral research in China.
- Chiron, one of the worlds leaders in vaccine research
- News of H5N1 research coming

http://www.theasianinvestor.com/reports/tedg.htm

[ballyhooo]

Techedge, Inc. Appoints Dr. Shu as CEO and Chief Scientist for China BioPharma
Tuesday April 4, 8:55 am ET


ISELIN, N.J.--(BUSINESS WIRE)--April 4, 2006--Techedge, Inc. (OTCBB:TEDG - News) today announced its appointment of Dr. Jean-Denis Shu (MD, MBA) as the CEO and Chief Scientist of its soon to be wholly owned subsidiary China BioPharma Limited.
ADVERTISEMENT


On February 13, 2006, Techedge, Inc. announced that it had signed a letter of intent to acquire China BioPharma Limited, a Cayman island Company, which has the rights to have majority ownership in one of the largest non-governmental owned vaccine development and manufacturing companies in China. The company's currently available products are vaccines against Influenza and Epidemic Hemorrhagic Fever. Techedge is in the process of preparing the legal document and expect to close this deal in Q2, 2006.

Formerly the Regional Director of Far East & North Pacific of Chiron Vaccines, Dr. Shu is widely recognized as a vaccine expert in China, with extensive experiences in business start-ups and general management in vaccine industry, proven track-record in medical and marketing management in France and China, and strong resource network. His past professional experiences also include General Delegate China for Aventis Pasteur, and Medical and Regulatory Affairs Manager for Pasteur Merieux Connaught, based in Lyon, France. Dr Shu was the author of several articles and books in vaccines.

A French citizen born in Shanghai, Dr. Shu is bi-cultural and tri-lingual (English, French and Chinese). He earned a Certificate of Finance and Accounting from Wharton School, a MBA from the European School of Management (ESCP-EAP) in Paris, a Diploma of Specialization on Gynecology-Obstetrics from Medical and Pharmacy College of Besancon in France, and a Medical Degree, B. Med. from Medical University of Shanghai II, in China. Dr Shu spent five years as Foreign Physician in French hospitals.

"As a witness and player, my career in vaccine industry has developed for ten years together with the growth of Chinese vaccine market that is one of the world fastest growing markets. I am very excited about this opportunity and am committed to lead China BioPharma to become a leading market player in China's enormous vaccine and bio-pharmaceutical industry", commented Dr. Shu.

[sweet crude]

surprised not more people...

We have a flu vaccine, are doing H5N1 research, unlike STTK....why not more people?

[sweet crude]

TEDG - current flu vaccine

http://www.theasianinvestor.com/reports/tedg.htm

[ballyhooo]

Techedge Inc. Issues Corporate Update
Techedge, Inc. (OTCBB:TEDG) Chairman and CEO Peter Wang today issued the following corporate update:

"We are pleased to provide our shareholders with the following corporate update:

"Techedge is repositioning itself for the fast growing bio-pharmaceutical sector in China. With its recently signed Letter of Intent with China BioPharma Limited, Techedge plans to quickly enter into this market with a major interest holding in one of the fast growing bio-pharmaceutical companies in China. Techedge is in the process of preparing the legal document and expect to close this deal in Q2, 2006. After closing this deal, Techedge expects to consolidate its annual sales at about $10 million and net income about $1.5 million. The Bio-pharmaceutical sector is one of the fastest growing sectors in China at about 25% annual growth. Current demand for vaccines of epidemic diseases such as SARS and Avian Bird Flu is growing rapidly. With the relationship and working experience through strategic partners and various government agencies in China, Techedge plans to team up and invest in other profitable and well-managed bio-pharmaceutical companies in China.

"Additionally, Techedge has terminated its long distant calling business in the beginning of this year. It will significantly cut its operational losses and improve its short-term financial conditions. Techedge is looking for strategic partners to carry out the commercialization of its unique and high potential Mobile Voice over IP solutions.

"As always, I appreciate your ongoing support and look forward to a successful 2006."

About Techedge, Inc.

Techedge Inc. (OTCBB:TEDG) is a leading developer of mobile VoIP and wireless broadband solution provider. The Company provides disruptive and low cost communications solutions combining matured radio with VoIP technologies for emerging service providers. The Company has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. For more information, please visit its website at www.techedgeinc.net.

FORWARD-LOOKING STATEMENT DISCLAIMER

Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.


Techedge Inc.
Tony Tsai, 732-632-9896, ext. 115
Fax: [phone]
[e-mail]

[gojonniego]

NGINetwork.com profiles Techedge, Inc. insiders purchase
NEW YORK, MAY 2, 2005 (PRIMEZONE) --
National Growth Investors Network announced April 28 a company overview of Techedge, Inc. ( OTC: TEDG. OB) The Profile was a comprehensive look at Techedge, Inc., the company's products and latest news. Insiders Peter Wang, Techedge's Chief Executive Officer and Chairman of the Board of Directors, and Ya Li, Techedge's Chief Financial Officer together purchase 95,000 shares in late April of 2005.

About Techedge Inc.
Techedge Inc. is a leading mobile Voice over IP (VoIP) solution provider. The Company provides disruptive and low cost communications solutions combining matured radio with VoIP technologies for emerging service providers. Techedge's IP-PCS solution is the first in the market to support VoIP with regional mobility on unlicensed frequencies for low-cost mobile VoIP services. Its core platform supports various radio technologies such as PACS-UB, Wi-Fi, and WiMax. The solution has been designed for rapid deployment in urban, resort, campus and local communities. For more information, please visit company's website located at http://www.techedgenetwork.com

You can view the complete profile at http://www.nginetwork.com.
About The National Growth Investors Network
NGINetwork.com publishes profiles on up and coming publicly traded Companies. NGINetwork.com is a leader in Internet Destinations for small cap stock information. To feature your company please contact us by email at [e-mail]
Disclosure: NGINetwork.com has been compensated by a third party $2500 for 1-month coverage and publication of this profile. Details can be found at http://www.NGINetwork.com Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties. This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words ``may,'' ``would,'' ``will,'' ``expect,'' ``estimate,'' ``anticipate,'' ``believe,'' ``intend,'' ``promise,'' ``seeking to,'' ``negotiating to'' and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Contact:
NGINetwork.com
Geoffrey Jones
[phone]
[e-mail]

Source: National Growth Investors Network

[gojonniego]

Press Release Source: National Growth Investors Network


National Growth Investors Network Announces Company Overview of Techedge, Inc.
Thursday April 28, 11:32 am ET


NEW YORK, April 28, 2005 (PRIMEZONE) -- The National Growth Investors Network today announced the company overview of Techedge, Inc. (OTC BB:TEDG.OB - News). The Profile is a comprehensive look at Techedge, Inc., the company's products and latest news. You can view the complete profile at http://www.nginetwork.com.
About Techedge Inc.

Techedge Inc. is a leading mobile Voice over IP (VoIP) solution provider. The Company provides disruptive and low cost communications solutions combining matured radio with VoIP technologies for emerging service providers. Techedge's IP-PCS solution is the first in the market to support VoIP with regional mobility on unlicensed frequencies for low-cost mobile VoIP services. Its core platform supports various radio technologies such as PACS-UB, Wi-Fi, and WiMax. The solution has been designed for rapid deployment in urban, resort, campus and local communities. For more information, please visit company's website located at http://www.techedgenetwork.com

[gojonniego]

New profile of TEDG on www.nginetwork.com